[Pathogenesis and treatment of portal encephalopathy].
D000471:Alkalosis / Q000188:drug therapy; D000472:Alkalosis, Respiratory / Q000188:drug therapy; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001120:Arginine / Q000627:therapeutic use; D001216:Asparagine / Q000627:therapeutic use; D001921:Brain / Q000098:blood supply; D003097:Collateral Circulation; D004035:Diet Therapy; D004044:Dietary Proteins; D004733:Enema; D005632:Fructose / Q000627:therapeutic use; D005690:Galactose / Q000627:therapeutic use; D006501:Hepatic Encephalopathy / Q000150:complications; D006801:Humans; D006975:Hypertension, Portal / Q000150:complications; D007511:Ischemia / Q000209:etiology / Q000628:therapy; D008107:Liver Diseases / Q000150:complications*; D008569:Memory Disorders / Q000209:etiology / Q000628:therapy; D001523:Mental Disorders / Q000150:complications* / Q000628:therapy; D009355:Neomycin / Q000009:adverse effects; D009422:Nervous System Diseases / Q000150:complications*; D009461:Neurologic Manifestations; D009952:Ornithine / Q000627:therapeutic use; D011167:Portacaval Shunt, Surgical / Q000009:adverse effects
D000900:Anti-Bacterial Agents; D004044:Dietary Proteins; D005632:Fructose; D001216:Asparagine; D001120:Arginine; D009952:Ornithine; D009355:Neomycin; D005690:Galactose
Pathogenese und Therapie der portalen Enzephalopathie.